EGFR and neutropenia: Compared with DPF, the NPF regimen effectively alleviated neutropenia (P = 0.018) and gastrointestinal reactions (P = 0.032) in the induction phase, while use of EGFR monoclonal antibody in human chemotherapy did not increase mucosal-related toxicity.